Every material Form 8-K CDT Equity Inc. has filed with the SEC since September 25, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Former CEO Dr. Andrew Regan, writing on behalf of Corvus Capital Limited, told the Board in a November 5, 2026 letter that Corvus intends to make a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium on a post-split basis to the November 4, 2026 closing price, absent a Board proposal. The Board intends to form a special committee of independent directors with full authority over the proposal, but the committee has received no definitive terms and has made no decision, and there is no assurance any transaction will result.
Letter dated November 5, 2026, from Dr. Andrew Regan, former CEO, as a significant stockholder, on behalf of Corvus Capital Limited
Proposed price of $2.00 per share, a 96.3% premium to the November 4, 2026 closing price, on a post-split basis
Board intends to form a special committee of independent directors with full authority to consider and vote on the proposal
No definitive terms received and no decision made; the company does not commit to provide updates
CDT Equity entered an evaluation agreement dated October 22, 2026, under which Manoira Corporation will assess CDT's clinical-stage compounds AZD1656 and AZD5904 for its animal healthcare products. CDT issued 1,347,616 common shares at $0.1447 per share to settle a $195,000 payment due to Manoira, and the filing also reports other share issuances in the same period. Because the deal is an evaluation with no stated licensing terms yet, its value to shareholders is not yet clear, while the share issuances add to the number of shares outstanding.
Evaluation agreement with Manoira dated October 22, 2026; Manoira is preparing a first range of animal health products for launch in the first quarter of 2027.
1,347,616 shares issued at $0.1447 per share to settle a $195,000 payment to Manoira.
Other unregistered issuances: 397,374 shares to a service provider, 437,779 shares to Sarborg Limited, and 499,616 shares to former CEO Dr. Andrew Regan in lieu of $65,000 severance.
Dr. Regan, a more-than-5% holder and sole director of Manoira, will receive no consideration from the Manoira deal; the filing lists one date as October 23, 3026, which appears to be a typo.
CDT Equity Inc. issued a $6,750,000 senior secured convertible note to J.J. Astor & Co. on October 6, 2026, to be funded in two tranches. The company received $3,000,000 in the first tranche and must repay the note in weekly installments starting October 14, 2026, with maturity on March 24, 2027. The lender can convert the note into common stock at a discounted price and received warrants for 225,000 shares, which could add shares outstanding for existing shareholders.
First tranche: $3,000,000 received against $4,050,000 of principal, with net proceeds of $2,869,850 after closing fees
Second tranche of $2,000,000 is subject to conditions on or before December 31, 2026, including a closing bid price of at least $3.00
Conversion price is the greater of 70% of the lowest closing price over 20 trading days or a $0.18354 floor; warrants for 225,000 shares at $0.9177
80% of net proceeds from the at-the-market offering with A.G.P. are applied to the note first; the note is secured by a first priority lien
CDT Equity Inc. said its board approved a 1-for-25 reverse stock split of its common stock to help maintain compliance with the Nasdaq bid-price rule. The split takes effect September 28, 2026, and every 25 shares will be combined into one share, with the par value unchanged at $0.0001.
Effective time is 5:00 p.m. Eastern Time on September 28, 2026; split-adjusted trading on Nasdaq begins at market open on September 29, 2026 under the ticker CDT.
After the split, outstanding shares are expected to be about 1,124,515, with a new CUSIP number of 20678X700.
No fractional shares will be issued; holders entitled to a fraction will receive a cash payment based on the September 28, 2026 closing price.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CDT Equity Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →